BioCardia, Inc. BCDA
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
BioCardia, Inc. (BCDA) is a healthcare company listed in the US with a market value of about $13M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -260%.
About BioCardia
BioCardia is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $904000 in 2015 to $58000 in 2024, a decline of about 26.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 62% over three years (buybacks).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $58000 | $477000 | $1M | $1M | $145000 | $710000 | $625000 | $479000 | $576000 |
| Net income | -$8M | -$8M | -$12M | -$12M | -$13M | -$15M | -$15M | -$14M | -$12M | -$10M |
| Free cash flow | -$7M | -$8M | -$10M | -$11M | -$10M | -$12M | -$10M | -$11M | -$9M | — |
| EPS (diluted) | $-1.23 | $-2.90 | $-8.19 | $-0.67 | $-0.75 | $-1.48 | $-2.61 | $-3.28 | $-2.90 | $-11.07 |
| Net margin | — | -13700.0% | -2425.8% | -880.7% | -1243.7% | -10347.6% | -2071.7% | -2237.9% | -2569.5% | -1789.9% |
| ROIC | -459.6% | -353.5% | — | -144.1% | -81.5% | -62.0% | -319.7% | -293.8% | -88.1% | -29.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $15.50, 1765% above the current price; targets range from $6.00 to $25.00; the consensus rating is “Strong buy”; expected EPS is $-0.63 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does BioCardia pay a dividend?
Not currently.
Is BioCardia a good stock to buy?
We do not give buy or sell advice. BioCardia scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.